115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Extended follow-up of efficacy and safety of larotrectinib in patients with TRK fusion lung cancer
    Meeting Abstract

    Moreno, V.; Lin, J. J.; Tan, D. S. W.; Kummar, S.; Dai, M. S.; Lassen, U. N.; Leyvraz, S.; Liu, Y.; Patel, J. D.; Rosen, L.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1/2 study of BLU-701, a highly selective EGFR inhibitor, in patients with EGFR-mutant non-small cell lung cancer
    Meeting Abstract

    Spira, A.; Spigel, D. R.; Camidge, R.; de Langen, A. J.; Kim, T. M.; Goto, K.; Elamin, Y.; Shum, E.; Reckamp, K. L.; Rotow, J.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1-positive solid tumors: The phase 1/2 ARROS-1 study
    Meeting Abstract

    Drilon, A.; Ou, S. H. I.; Gadgeel, S.; Johnson, M.; Spira, A.; Lopes, G.; Besse, B.; Felip, E.; van der Wekken, A. J.; Calles, A.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1/2 study of BLU-451, a small molecule inhibitor of EGFR, in EGFR exon 20 insertion-mutant incurable advanced cancers
    Meeting Abstract

    Spira, A.; Yu, H.; Sun, L.; Nguyen, D.; Parepally, J.; Albayya, F.; Patel, S.; Zhang, H.; Zalutskaya, A.; Le, X.
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Alessi, J.; Elkrief, A.; Ricciuti, B.; Cortellini, A.; Wang, X.; Vaz, V. R.; Barrichello, A.; Lamberti, G.; Fulgenzi, C.; Pecci, F.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Trial in progress: A phase 2 multicenter study (IOV-LUN-202) of autologous tumor-infiltrating Lymphocyte (TIL) cell therapy (LN-145) in mNSCLC
    Meeting Abstract

    Chesney, J. A.; Schoenfeld, A. J.; Wise-Draper, T.; Sukari, A.; He, K.; Graf Finckenstein, F.; Hari, P.; Jagasia, M.; Samakoglu, S.; Leighton-Swayze, A.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • External validation of a novel CT-based prognostic radiomic signature in patients with metastatic NSCLC in SWOG S0819 phase III randomized trial
    Meeting Abstract

    Dercle, L.; Gomez, D.; Zhao, B.; Kelly, K.; Herbst, R. S.; Redman, M. W.; Gandara, D. R.; Schwartz, L. H.
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Phase II NAUTIKA1 study of targeted therapies in stage II-III NSCLC: Preliminary data of neoadjuvant alectinib for ALK+ NSCLC
    Meeting Abstract

    Lee, J. M.; Sepesi, B.; Toloza, E. M.; Pass, H. I.; Lin, J.; Johnson, B. E.; Heymach, J. V.; Johnson, M. L.; Ding, B.; Schulze, K.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Circulating tumor DNA to identify genomic biomarkers of radiation sensitivity in locally advanced non-small cell lung cancer
    Meeting Abstract

    Lebow, E.; Li, B. T.; Sheverdian, N.; Eichholz, J.; Kratochvil, L. B.; Gelblum, D. Y.; Simone, C. B. 2nd; Shepherd, A. F.; Shin, J. Y.; Rimner, A.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Planned interim analysis of a phase II trial of concurrent durvalumab and radiation therapy for locally advanced lung cancer
    Meeting Abstract

    Rimner, A.; Fitzgerald, K.; Iqbal, A. N.; Shepherd, A. F.; Gomez, D. R.; Shin, J. Y.; Gelblum, D. Y.; Hajj, C.; Albrecht, F.; Kotecha, R. R.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save